Lactobacillus rhamnosus

Condiciones de salud que Lactobacillus rhamnosus puede ayudar a apoyar.

• DislocaciónCientífico

  Lactobacillus rhamnosus (particularly LGG and other strains) has been shown in clinical trials and meta-analyses to reduce abdominal pain in IBS. A systematic review of 104 RCTs found L. rhamnosus among the highest-efficacy probiotic formulations for abdominal pain and quality of life improvement.

• AbrasionesCientífico

  Lactobacillus rhamnosus is included in multi-strain probiotic formulations demonstrating GERD benefit in the 2020 systematic review (13 studies, 79% positive GERD comparisons, n=951). It improves gut barrier integrity via tight junction upregulation, reduces pro-inflammatory cytokines, and may reduce gastric dysbiosis linked to GERD. Most evidence derives from multi-strain probiotic studies rather than standalone L. rhamnosus RCTs.

• AbscesosCientífico

  Clinical and preclinical evidence supports L. rhamnosus supplementation improving acne vulgaris outcomes via the gut-skin axis. A 12-week RCT using L. rhamnosus CECT 30031 found 50% of patients improved on the Acne Global Severity Scale versus 29% with placebo (p=0.03). Animal studies show L. rhamnosus reduces acne-associated inflammation by modulating gut microbiota and tryptophan metabolism. Gene-level studies document normalization of insulin-signaling and IGF-1 expression in skin.

• Abuso y TraumaCientífico

  L. rhamnosus GG has been studied for immunomodulation of respiratory allergies via the gut-lung axis. Multiple clinical trials using LGG as adjunct to allergy immunotherapy or corticosteroids showed improved immune responses and quality of life. Murine asthma models demonstrate that early oral LGG reduces airway inflammation and hyperreactivity. Results in humans are mixed across different formulations and populations.

• Acidez EstomacalCientífico

  L. rhamnosus HN001 reduced postpartum anxiety scores in a landmark 423-person double-blind RCT. The strain JB-1 consistently shows anxiolytic effects in animal models via GABA-dependent gut-brain signaling. Mechanistically, L. rhamnosus modulates the HPA axis and corticosterone response. Evidence is strongest for postpartum anxiety and stress-induced anxiety models.

• EdemaCientífico

  Murine asthma models consistently show that oral L. rhamnosus attenuates airway inflammation, hyperreactivity, and gut microbiome dysbiosis associated with allergic asthma. L. rhamnosus GR-1 prevented airway function deterioration in a birch-pollen mouse model. Human clinical evidence remains limited and mixed, with several RCTs showing no significant benefit.

• Contaminación ElectromagnéticaCientífico

  L. rhamnosus modulates immune tolerance mechanisms relevant to autoimmune pathology, including Th17/Treg balance, intestinal barrier integrity, and IL-10 production. LGG has been studied in IBD—a prototypic autoimmune-related condition—and shown to reduce colonic inflammation via the STING pathway. It has also been studied in celiac disease models, rescuing BDNF disruption caused by gliadin.

• Adicciones (azúcar o carbohidratos refinados)Científico

  Lactobacillus rhamnosus inhibits the growth of Porphyromonas gingivalis, Prevotella intermedia, and Tannerella forsythia—primary VSC-producing bacteria responsible for halitosis. An in vitro microbiological study published in PMC (2023) confirmed L. rhamnosus inhibitory effects against these halitosis-causing bacteria. A 2021 comprehensive review confirmed mechanistic support for its role in reducing the pathogen load responsible for VSC generation.

• Enfermedad de AddisonCientífico

  Lactobacillus rhamnosus GR-1 is among the best-evidenced probiotic strains for urinary tract and bladder health. The European Association of Urology guidelines recommend it for prevention of recurrent UTIs. Studies show it reduces UTI recurrence by competitive exclusion of uropathogens, immunomodulation, and maintaining urogenital flora balance.

• Fatiga SuprarrenalCientífico

  Clinical trials show L. rhamnosus supplementation can stabilize glycemic markers in at-risk populations. A 90-day placebo-controlled RCT demonstrated that LGG prevented an increase in HbA1c in middle-aged adults (p=0.005). The HN001 strain in pregnancy reduced conjugated bile acids and improved glucose metabolism in women at risk for gestational diabetes.

• Manchas de la edadCientífico

  L. rhamnosus GG has been shown to ameliorate bone loss and improve bone microarchitecture in animal models via Th17/Treg immune regulation. The gut-bone axis is a recognized pathway whereby gut microbiota modulate osteoclast formation through immune signaling. Postmenopausal osteoporosis models in rodents show protective effects of LGG on trabecular bone. Human clinical evidence remains largely indirect via the broader probiotic-bone literature.

• AlcoholismoCientífico

  L. rhamnosus HN001 administered during pregnancy and continued through breastfeeding was evaluated in a 423-person RCT, reducing postpartum depression and anxiety symptoms in lactating women. LGG administration during lactation has been shown to alter mammary gland and breast milk microbiota in animal models. Separate work supports L. rhamnosus immune modulation in the mammary gland context.

• Fístula anal o fisuraCientífico

  Lactobacillus rhamnosus GR-1 is among the most clinically validated probiotic strains for Candida inhibition. An RCT demonstrated significant reductions in vaginal yeast colonization. In vitro studies confirm potent candidacidal activity and biofilm disruption against C. glabrata, and it is identified in a 2024 review of 25 clinical studies as a top evidence-supported strain for VVC management.

• Energía (falta de)Científico

  Lactobacillus rhamnosus GG is among the most clinically studied probiotic strains, with demonstrated activity in restoring gut microbiota balance disrupted by antibiotic use—a primary risk factor for Candida overgrowth. It produces antifungal metabolites and competes with Candida for epithelial adhesion sites, making it a standard component of Candida cleanse probiotic protocols.

• Contaminación AmbientalCientífico

  Lactobacillus rhamnosus CCT 7863 was used in a 2025 randomized controlled trial (PMID 40699044, 85 CeD patients) in combination with Bifidobacterium lactis, concluding probiotics are beneficial adjunct therapy for CeD providing symptom relief and quality of life improvement. L. rhamnosus strains are noted in CeD literature for gut barrier integrity enhancement properties relevant to the increased intestinal permeability in CeD.

• AnorexiaCientífico

  Multiple randomized controlled trials (RCTs) have evaluated Lactobacillus rhamnosus strains in children with atopic dermatitis (eczema) and cow's milk protein allergy. A 2021 multicenter RCT of 151 children under age 2 found a probiotic preparation including L. rhamnosus ŁOCK strains superior to placebo in improving SCORAD severity scores, especially in allergen-sensitized patients. The strain modulates Th1 cytokines and regulatory IL-10 while suppressing pro-allergic IL-5. A 2025 network meta-analysis identified Lactobacillus rhamnosus GG (LGG) as standout for pediatric food allergy management.

• Antibióticos (efectos secundarios de los)Científico

  Lactobacillus rhamnosus GG (LGG) is among the best-evidenced probiotic strains for children's digestive health globally. Multiple systematic reviews confirm its efficacy in treating acute gastroenteritis and preventing antibiotic-associated diarrhea in children. It is specifically recommended in multiple international pediatric GI guidelines.

• AnsiedadCientífico

  Lactobacillus rhamnosus (especially the LGG strain) is among the most extensively studied probiotics for reducing respiratory tract infections in children. In a RCT of 281 children in daycare, LGG significantly reduced upper respiratory tract infections and lowered the risk of infections lasting more than 3 days. A 2015 Cochrane review found probiotics including Lactobacillus strains reduced URTI episodes, duration, and antibiotic use in children.

• Válvula IleocecalCientífico

  Clinical RCTs with L. rhamnosus strains have demonstrated improvements in LDL cholesterol and HDL-C levels. A randomized trial in elderly subjects showed significant LDL-C improvement in the probiotic group (p=0.045) at 8 weeks. L. rhamnosus LRa05 in a type 2 diabetes RCT produced a significant time-dependent cholesterol reduction (p=0.0164) and markedly improved HDL-C (p<0.0001).

• ApendicitisCientífico

  L. rhamnosus GG reduces chronic intestinal inflammation by inducing IL-10 production in intestinal monocytes via the STING/TBK1/NF-κB signaling pathway. It also modulates gut microbiota composition, reducing proinflammatory cytokine production. In acne, animal, and IBD models, LGG consistently lowers TNF-α and IL-6 levels.

• ArteriosclerosisCientífico

  Lactobacillus rhamnosus has been included in multi-strain probiotic combinations studied for infantile colic, with one combination reducing daily crying duration by approximately 35 minutes versus placebo. It is a well-studied probiotic for pediatric gastrointestinal conditions. Evidence for colic is primarily as part of combination probiotic products.

• Estrógeno (bajo)Científico

  Lactobacillus rhamnosus GG (LGG) is among the most extensively studied probiotics for ulcerative colitis, with documented mucosal adhesion capacity, anti-inflammatory activity, and a favorable safety profile across clinical trials. It has been evaluated as monotherapy in mild-to-moderate UC, and is commonly studied in combination with Bifidobacterium.

• ArtritisCientífico

  Lactobacillus rhamnosus (including strains LR22 and HN001) is a probiotic with demonstrated efficacy in constipation. L. rhamnosus HN001 combined with Bifidobacterium animalis in a 4-week RCT in 250 adults with functional constipation significantly improved Bristol Stool Scale scores vs. placebo. Animal studies confirm L. rhamnosus colonizes the intestinal tract and reduces constipation indicators.

• Ojos (rojos o con picazón)Científico

  A double-blind RCT (Bousvaros et al. 2005, Inflamm Bowel Dis) evaluated LGG versus placebo as adjunct to standard maintenance therapy in children with Crohn's disease. While LGG has anti-inflammatory effects in intestinal models and modulates gut microbiota, the clinical RCT in Crohn's disease did not demonstrate a significant therapeutic advantage over standard therapy alone.

• Trastorno por Déficit de AtenciónCientífico

  A 423-person double-blind RCT (Slykerman et al. 2017) found L. rhamnosus HN001 significantly reduced postpartum depression scores in women. Mechanistic animal studies show LGG modulates BDNF levels in brain tissue and reduces xanthine oxidase activity linked to depressive phenotypes. The gut-brain axis, through neuroendocrine and immune pathways, underpins these effects.

• Vista (deficiente)Científico

  Lactobacillus rhamnosus (notably GG strain) is among the most studied probiotic strains for atopic dermatitis. Meta-analyses and systematic reviews document its study in RCTs for both prevention and treatment of AD in children and adults, with modest SCORAD reductions reported in some trials.

• Trastornos AutoinmunesCientífico

  Lactobacillus rhamnosus (including strain GG) is consistently supported by Cochrane reviews and meta-analyses for reducing diarrhea duration and preventing antibiotic-associated diarrhea in children and adults. A Cochrane review (33 RCTs, 6352 children) identified L. rhamnosus at 5–40 billion CFU/day as one of the most appropriate strains for preventing antibiotic-associated diarrhea.

• Retraso del crecimientoCientífico

  Lactobacillus rhamnosus is among the most extensively studied probiotic strains globally, with established evidence for immune modulation and gut microbiota diversity maintenance. It is identified as a contributing strain in multi-strain probiotic formulations showing benefit in diverticular disease, and is specifically referenced in diverticulitis probiotic evidence summaries.

• Parálisis de BellCientífico

  Lactobacillus rhamnosus (particularly the GG strain) is the most extensively studied probiotic for atopic eczema, with multiple RCTs and systematic reviews demonstrating reduced eczema prevalence and severity, especially in high-risk infants and children. A double-blind RCT found L. rhamnosus HN001 halved cumulative eczema prevalence at 2 and 4 years.

• Síndrome de DownCientífico

  Lactobacillus rhamnosus GG (LGG) is the most studied probiotic strain for food allergy and sensitivity. RCTs show it aids tolerance acquisition in cow's milk protein allergy (CMPA) and reduces atopic dermatitis severity. Combined with peanut oral immunotherapy, it induced sustained unresponsiveness in 82% of peanut-allergic children. Evidence supports strain-specific immune modulation including mast cell inhibition.

• Envenenamiento de la sangreCientífico

  Lactobacillus rhamnosus (notably strain GG) is among the most researched probiotic strains for gut barrier support and has been studied in clinical trials for food allergy and intolerance. Pre- and postnatal supplementation with L. rhamnosus GG has shown effects on reducing food allergy risk and modulating gut permeability in clinical studies.

• Enfermedad del Hígado GrasoCientífico

  Lactobacillus rhamnosus GG is one of the most studied probiotic strains for H. pylori eradication and gastritis management. It is specifically identified in systematic reviews and meta-analyses as effective in increasing H. pylori eradication rates and reducing side effects of antibiotic therapy for H. pylori gastritis.

• Bultos en el SenoCientífico

  Lactobacillus rhamnosus strains have been evaluated in multiple RCTs for gingivitis and periodontitis management and are among the most frequently studied probiotic strains in periodontal RCTs after L. reuteri. A Frontiers in Dental Medicine review of 36 periodontal RCTs identified various L. rhamnosus strains as second most frequently evaluated probiotic strains for periodontal conditions.

• Leche materna (secar)Científico

  Lactobacillus rhamnosus GG (LGG) is the world's most studied probiotic strain with the strongest clinical evidence base for gut microbiome health, including prevention of antibiotic-associated diarrhea, C. difficile prevention, IBS improvement, and gut microbiota modulation in infants, children, and adults.

• Senos (aumentar tamaño)Científico

  Lactobacillus rhamnosus (particularly strain GG and JB-1) has some of the most mechanistically detailed gut-brain axis evidence. Animal studies definitively established that L. rhamnosus JB-1 alters GABA receptor expression in the brain via the vagus nerve, with vagotomy abolishing all effects. Human RCTs show L. rhamnosus GG improves memory performance and shifts gut microbiota composition.

• Moretones (prevención)Científico

  Lactobacillus rhamnosus CGMCC1.3724 has demonstrated sex-specific weight loss effects in clinical trials. A 2014 double-blind RCT in 125 obese men and women over 24 weeks found women taking L. rhamnosus lost significantly more weight (1.8 kg more) and continued to lose weight during the maintenance phase, unlike placebo, via modulation of appetite-regulating hormones and gut microbiota.

• PulgasCientífico

  Lactobacillus rhamnosus GG has meta-analytic evidence for IBS efficacy confirmed in a 2025 strain-specific systematic review (32 RCTs, 10 strains). It is specifically named as one of the best-evidenced individual probiotic strains for IBS. A 2017 systematic review specifically identified L. rhamnosus as among the probiotics effective for ameliorating IBS symptoms.

• FlotadoresCientífico

  Lactobacillus rhamnosus GG (LGG) is one of the best-studied probiotic strains in IBD. Multiple clinical trials demonstrate its efficacy in UC remission maintenance and as adjunct therapy, with LGG listed among the most commonly used probiotics in IBD RCTs.

• Olor de piesCientífico

  L. rhamnosus GG improves insulin sensitivity in high-fat-diet animal models by enhancing GLUT4 expression in skeletal muscle, increasing adiponectin, and activating AMPK. A 90-day RCT showed LGG stabilized HbA1c in middle-aged adults. HN001 in pregnancy reduced fasting conjugated bile acids correlated with improved insulin indices.

• CataratasCientífico

  Lactobacillus rhamnosus HN001 combined with Bifidobacterium longum BB536 and vitamin B6 was evaluated in a randomized, double-blind, crossover study (n=23) of lactose-intolerant patients, demonstrating alleviation of persistent GI symptoms and favorable microbiome changes. Systematic reviews include L. rhamnosus among strains with demonstrated benefit in LI.

• Vesícula Biliar (perezosa o extirpada)Científico

  Lactobacillus rhamnosus (including the LGG strain) is one of the best-documented probiotic strains for intestinal barrier restoration. Multiple RCTs and systematic reviews demonstrate it reduces colonic permeability and serum zonulin in IBS patients. A crossover double-blind RCT in 25 IBS patients showed Bifidobacterium longum BB536 combined with L. rhamnosus HN001 reduced colonic permeability in patients with elevated baseline permeability.

• GingivitisCientífico

  Lactobacillus rhamnosus, particularly the GG (LGG) and CGMCC1.3724 (LPR) strains, has been studied in human clinical trials and numerous preclinical models for its effects on key components of metabolic syndrome, including obesity, insulin resistance, dyslipidemia, and dysbiosis. A 2014 double-blind RCT found that L. rhamnosus LPR supplementation supported significant weight loss in obese women compared to placebo. A 2025 systematic review of 51 RCTs confirmed potential benefits of L. rhamnosus across metabolic and other conditions. Mechanistic evidence points to gut microbiota modulation, short-chain fatty acid production, improved GLP-1 secretion, and enhanced insulin sensitivity, though human evidence is still maturing and effects appear strain-dependent.

• BocioCientífico

  Lactobacillus rhamnosus is the most clinically studied probiotic bacterium for human mycotoxin (aflatoxin) reduction. An RCT with L. rhamnosus LC705 plus Propionibacterium freudenreichii in young Chinese men demonstrated a statistically significant reduction in aflatoxin biomarkers over 5 weeks, associated with decreased liver cancer risk. LAB including L. rhamnosus produce metabolites that mitigate mold growth and directly bind mycotoxins via cell wall interactions.

• ColitisCientífico

  L. rhamnosus can synthesize and release GABA, modulating GABAergic neurotransmitter signaling via the gut-brain axis. It also influences brain BDNF levels, a key neurotrophin. Preclinical and mechanistic studies show that gut microbiota dysbiosis disrupts neurotransmitter signaling, and LGG can partially restore these pathways.

• Conmociones cerebralesCientífico

  Lactobacillus rhamnosus GG and other strains have been assessed in multiple RCTs for effects on the oral microbiome, including salivary mutans streptococci levels, plaque, and gingival inflammation. A 4-week RCT combining LGG and Bifidobacterium lactis BB-12 demonstrated measurable changes in oral microbiota composition in healthy adults. Clinical evidence suggests benefit for gingivitis reduction.

• Infección (bacteriana)Científico

  L. rhamnosus GG demonstrates bone-protective effects in ovariectomized animal models by correcting Th17/Treg imbalance and improving bone microarchitecture, biomechanics, and turnover markers. A 2010 double-blind RCT documented improved bone mineral density and bone turnover markers in postmenopausal women. The gut-bone axis is a mechanistically supported pathway.

• Cabello (pérdida o adelgazamiento)Científico

  Lactobacillus rhamnosus is one of the Lactobacillus strains explicitly included in multi-strain probiotic RCTs for PCOS showing improved metabolic and hormonal outcomes. It is listed in the Advances in Nutrition 2022 review as a constituent of evidence-supported probiotic regimens in PCOS.

• ConjuntivitisCientífico

  One of the most clinically studied probiotic strains, L. rhamnosus supports immune function, reduces duration and severity of respiratory illness, and helps restore gut microbiome balance during post-illness recovery. Multiple RCTs demonstrate its efficacy in reducing respiratory illness in various populations.

• Estreñimiento (niños)Científico

  Lactobacillus rhamnosus (GG strain) is one of the best-documented probiotic strains for perioperative use, with multiple RCTs demonstrating reduced post-surgical infectious complications, C. difficile rates, and hospital stay. It is explicitly included in ESPEN colorectal surgery perioperative nutrition guidelines.

• Enfermedades ContagiosasCientífico

  Lactobacillus (Lacticaseibacillus) rhamnosus is one of three specific probiotic species identified in a 2025 PMC systematic review (PMC12566607) as having clinical trial evidence for alleviating long-term COVID-19 symptoms post-viral. It is one of the best-studied probiotic strains globally for immune modulation and gut barrier restoration.

• ConvalecenciaCientífico

  Lactobacillus rhamnosus (particularly GG strain) is among the most-studied probiotics for postpartum use, with evidence for reducing postpartum depression risk, supporting gut microbiome restoration, and decreasing infant atopic disease when supplemented perinatally. A Finnish RCT (n=256) found perinatal L. rhamnosus GG supplementation significantly reduced postpartum depressive and anxiety symptoms at 6 months.

• ConvulsionesCientífico

  Lactobacillus rhamnosus (particularly strain GG) is one of the most-studied probiotic strains in pregnancy, with RCT evidence supporting reductions in gestational diabetes mellitus risk, preterm birth-associated complications, and neonatal atopic disease. A landmark RCT found L. rhamnosus GG significantly reduced GDM incidence (13% vs. 36%, p=0.003) from first trimester supplementation. International expert consensus (2025) included probiotics among supplements reviewed for pregnancy.

• Tos (seca)Científico

  L. rhamnosus GG has been evaluated in multiple clinical trials for seasonal allergic rhinitis, with mixed but overall suggestive evidence. As add-on to immunotherapy in children (n=100), LGG enhanced immune responses versus immunotherapy alone. LGG combined with L. gasseri in fermented milk alleviated nasal blockage symptom scores in adults with Japanese cedar pollinosis.

• Tos (general)Científico

  Lactobacillus rhamnosus strains have been studied in RCTs for seasonal allergic rhinitis. A 2016 meta-analysis of 22 RDBPCTs found probiotics including Lactobacillus strains produced significant reductions in nasal and ocular symptom scores (SMD -1.23, p<0.001 and SMD -1.84, p<0.001) and quality-of-life measures vs. placebo in allergic rhinitis.

• Envenenamiento por Metales PesadosCientífico

  Lactobacillus rhamnosus (especially strain GG) has been included in SIBO probiotic protocols based on its well-documented effects on intestinal permeability and immune modulation. Clinical evidence places it among probiotic strains with evidence for managing SIBO-related gut dysbiosis and symptoms, including its recognition in systematic reviews and clinical protocol documents.

• Fibrosis QuísticaCientífico

  L. rhamnosus HN001 demonstrated improvements in stress, happiness, and anxiety measures in a double-blind RCT of 120 stressed adults (PSS-defined), though changes did not reach statistical significance. A 2025 systematic review of animal studies confirmed consistent stress-reducing effects of L. rhamnosus JB-1 via HPA axis modulation. GABA synthesis and cortisol regulation are the primary proposed mechanisms.

• DefensividadCientífico

  A 571-child double-blind RCT found LGG supplementation produced a 17% relative reduction in respiratory infections with complications and lower respiratory tract infections. L. rhamnosus D3189 reduced RSV shedding and modulated innate immune responses in nasal epithelial cells in vitro. A patent-protected RCT demonstrated fewer illness days and lower severity scores in the probiotic group versus placebo for upper respiratory tract infections.

• DeshidrataciónCientífico

  Lactobacillus rhamnosus (particularly strain GR-1) is one of the most evidence-supported probiotic strains for urinary flora support, specifically recommended by the European Association of Urology for recurrent UTI prevention. Oral supplementation with L. rhamnosus GR-1 has been shown in RCTs to restore Lactobacillus populations in the vaginal and urinary microbiome and reduce recurrent UTI incidence. L. rhamnosus secretes immunomodulatory proteins in bladder cells and inhibits UPEC virulence and biofilm formation.

• Llagas por DentaduraCientífico

  Lactobacillus rhamnosus (particularly strain GR-1) is among the most studied Lactobacillus strains for prevention of recurrent urinary tract infections. A meta-analysis and multiple RCTs support its role in reducing UTI recurrence in adult women, with one double-blind study showing significant reduction in recurrence rates compared to control. The mechanism involves vaginal and urogenital colonization, preventing pathogen adhesion.

• HipoCientífico

  Lactobacillus rhamnosus, especially strain GR-1, is one of the most studied probiotics for UTI prevention in women. Multiple RCTs and a systematic review support its use, primarily in combination with L. reuteri RC-14, for reducing recurrent UTI frequency. The mechanism involves vaginal colonization, competitive exclusion of uropathogens, and production of lactic acid and hydrogen peroxide.

• DermatitisCientífico

  Lactobacillus rhamnosus strains GR-1 and BMX 54 are among the most extensively studied oral and vaginal probiotics for bacterial vaginosis treatment and prevention. Oral GR-1 (combined with L. reuteri RC-14) restores vaginal Lactobacillus dominance and reduces BV-associated bacteria via lactic acid and bacteriocin production. A systematic review of multiple RCTs confirmed efficacy of GR-1 for restoring vaginal pH and flora.

Sistemas corporales que Lactobacillus rhamnosus puede ayudar a apoyar.

• No hay sistemas corporales disponibles.